Sauleda S, Esteban J I, Altisent C, Puig L, Esteban R, Guardia J
Centre de Transfusió i Banc de Teixits, Servei Català de la Salut, Barcelona, Spain.
Thromb Haemost. 2000 Jun;83(6):807-10.
Hepatitis C virus (HCV) infected hemophiliacs respond at low rate to interferon (IFN) monotherapy.
To assess efficacy of IFN and RBV in HIV negative hemophiliacs with chronic hepatitis C and identify early predictive factors of response.
Twenty naive patients were treated with interferon and RBV for twelve months. Response was assessed by both serial ALT and HCV RNA levels.
Normalization of ALT with clearance of HCV RNA occurred in seven (35%) patients. Age and age at infection were the only features associated with a higher likelihood of response. In all responders the viral load had decreased by at least one log within two months of starting treatment.
Combination of interferon and ribavirin is well tolerated by hemophiliacs who achieve similar sustained response rates to non-hemophiliacs. Quantitative assessment of viral load at two months of treatment is a useful method to identify non-responders at an early stage.
丙型肝炎病毒（HCV）感染的血友病患者对干扰素（IFN）单一疗法反应率较低。
评估干扰素和利巴韦林（RBV）对慢性丙型肝炎的HIV阴性血友病患者的疗效，并确定早期反应预测因素。
20例初治患者接受干扰素和利巴韦林治疗12个月。通过连续检测ALT和HCV RNA水平评估反应。
7例（35%）患者ALT恢复正常且HCV RNA清除。年龄和感染时年龄是与更高反应可能性相关的唯一特征。所有有反应者在开始治疗的两个月内病毒载量至少下降了一个对数。
血友病患者对干扰素和利巴韦林联合治疗耐受性良好，其持续反应率与非血友病患者相似。治疗两个月时对病毒载量进行定量评估是早期识别无反应者的有用方法。
